A Byline by Austin Stevenson, ACT LAB
For U.S. cannabis companies, the conversation around rescheduling has understandably centered on domestic consequences: tax relief, access to capital, scientific research, financial services, and the slow normalization of an industry that has operated for years under contradiction.
But there is another question taking shape beyond U.S. borders: Could rescheduling eventually help American cannabis companies participate more meaningfully in European medical cannabis markets?
The answer is yes, but only with important caveats.
Rescheduling alone will not suddenly open European supply chains to U.S. cannabis. Europe has built its medical cannabis market around Good Manufacturing Practice standards, rigorous documentation, validated testing methods, and highly controlled pharmaceutical quality systems. Those expectations are not going away because the U.S. changes federal scheduling.
Still, a move toward Schedule III could begin removing some of the structural barriers that have kept U.S. operators from preparing for those standards in the first place. If cannabis companies have improved access to capital, better tax treatment, and fewer barriers to scientific collaboration, they can invest more seriously in the systems required to compete globally. That is where the real opportunity sits.
For years, many U.S. cannabis businesses have been forced to build around fragmented state regulations. Operators have had to meet the rules of California, Michigan, New York, or Nevada — all without a clear federal framework or a realistic pathway to international alignment. The result has been a highly innovative industry, but one where quality expectations can vary widely by market.
Europe looks at cannabis through a different lens. In European medical markets, the question is not simply whether a product passes a compliance panel. The question is whether the entire quality system can be trusted.
It’s an important distinction. Good Agricultural and Collection Practice cultivation is only one part of the pathway. Products entering European medical supply chains must also meet expectations around GMP processing, analytical validation, stability, traceability, documentation, and batch release. A clean test result is important, but it is not the same thing as a mature, validated quality system.
This is where U.S. operators need to be careful. Rescheduling may create more room to invest, but capital alone will not satisfy European regulators, importers, physicians, or patients. Companies will need consistent products, validated methods, reliable analytical data, and strong documentation practices that hold up across borders. The companies that begin preparing now will be in a far stronger position if regulatory and trade pathways become more accessible in the future.
The same is true for research. One of the most significant benefits of moving cannabis out of Schedule I is that it could make research more practical. Schedule I has created major administrative hurdles for clinical studies, product development, and collaboration between the cannabis industry, academic institutions, and health care systems. Those barriers have limited the kind of science that a mature medical market requires.
Schedule III removes some of the obstacles that have prevented better science from happening at scale.
That change could encourage more work around dosing consistency, product stability, bioavailability, formulation science, and long-term safety. It could also support more rigorous research into advanced product categories including beverages, nanoemulsions, edibles, inhaled products, and other novel delivery systems where consumer experience can vary considerably.
From a laboratory perspective, one of the most valuable outcomes would be stronger analytical science. Greater collaboration between laboratories, researchers, and manufacturers could accelerate the development of validated analytical methods, reference standards, proficiency testing, and stronger inter-laboratory comparability.
Cannabis has evolved quickly as a consumer product category in the United States. Product innovation has moved faster than the scientific and regulatory systems built to evaluate it. That gap becomes more obvious as the industry looks toward medical markets, international supply chains, and more sophisticated patient expectations.
Europe has taken a more clinical and regulatory path. The U.S. has largely driven product innovation, developing new formats, formulations, and consumer experiences at a pace few other markets have matched. The next stage of global cannabis development may depend on bringing those two strengths together.
That will require a more serious approach to testing and quality from the start.
This applies to flower as much as it does to manufactured products. Flower remains one of the largest categories in cannabis, even though traditional patent incentives are less obvious than they might be for a formulation, device, or pharmaceutical product.
That does not mean flower research lacks value. There is still a tremendous amount to learn about consistency, cultivation practices, terpene preservation, cannabinoid expression, stability, and shelf life. There is also a growing need for better data on how remediation, irradiation, drying, curing, handling, packaging, and environmental conditions influence chemistry and long-term product quality.
Even when traditional patent protection is limited, research can create value through process knowledge, proprietary datasets, cultivation protocols, genetics, trade secrets, and measurable product consistency. As the industry matures, flower can move beyond strain names and marketing claims toward more complete characterization based on measurable chemotypes and repeatable product attributes.
That shift would benefit both medical and adult-use markets. For medical cannabis in particular, consistent batch-to-batch performance may ultimately matter more than whether the underlying product can be patented. Physicians, pharmacists, regulators, and patients are all looking for greater predictability. Reliable analytical data can help provide it.
The same principle applies to international expansion.
There is clearly growing interest in Europe among U.S. cannabis companies, but interest is not the same as sustained investment. Relatively few U.S. operators have established a durable European operating infrastructure, and Europe is far from a single unified market. Reimbursement systems, prescribing practices, import rules, patient access, and commercial economics vary significantly from country to country.
Schedule III changes the conversation. It could make international growth strategies more realistic by improving balance sheets, creating more normalized business conditions, and encouraging stronger research partnerships. But it does not eliminate the complexity of European markets.
The companies most likely to succeed internationally will not simply be the best financed. They will be the ones that have already invested in robust quality systems, reliable testing, strong documentation, and transparent compliance.
That is the larger lesson of rescheduling. The U.S. cannabis industry may be entering a new phase, but global credibility will not come from policy change alone. It will come from the work companies do after policy begins to shift. It will come from stronger science, better data, consistent products, and quality systems that can withstand scrutiny across jurisdictions.
Rescheduling may open the door, but quality will decide who is ready to walk through it.
About Austin Stevenson
Austin Stevenson is Chief Revenue Officer of ACT LAB, where he leads commercial strategy for a private equity-backed testing platform spanning life sciences and regulated product markets. He specializes in scaling businesses through critical growth stages, aligning operations for expansion and future acquisition.
Disclaimer: Bylines by external contributors must not reflect the opinion of the editorial team.